Solomon
Solomon Afelik, Cleveland, OH US
Patent application number | Description | Published |
---|---|---|
20150368616 | METHODS FOR INDUCTION OF CELL FATES FROM PLURIPOTENT CELLS - A method of inducing pancreatic fates from human multipotent or pluripotent cells includes obtaining a cell population comprising human multipotent or pluripotent cells and providing the cell population with at least three of (i) an CXCR4 agonist, (ii) an EGFR agonist, (iii) an FGFR agonist, (iv) an Activin receptor agonist or an agent that stimulates SMAD3, (v) an IL11R agonist or IL6R agonist, (vi) a notch agonist, (vii) an RXR agonist or RAR agonist, or (viii) a BMP inhibitor for a time effective to allow the differentiation of pancreatic precursor cells from the human multipotent or pluripotent cells. | 12-24-2015 |
Solomon Azouz, Dallas, TX US
Patent application number | Description | Published |
---|---|---|
20110152305 | FILMS AND PARTICLES - Described herein are compounds and processes that can be used to prepare polymer-based films, particles, gels and related compositions, and processes for delivery of agents, and other uses. | 06-23-2011 |
20120107365 | FILMS AND PARTICLES - Described herein are compounds and processes that can be used to prepare polymer-based films, particles, gels and related compositions, and processes for delivery of agents, and other uses. | 05-03-2012 |
20130195954 | FILMS AND PARTICLES - Described herein are compounds and processes that can be used to prepare polymer-based films, particles, gels and related compositions, and processes for delivery of agents, and other uses. | 08-01-2013 |
Solomon Brown, Romeoville, IL US
Patent application number | Description | Published |
---|---|---|
20150366827 | COMPOSITIONS AND METHODS FOR MIXING AND APPLYING MIXED OXIDANT COMPOSITIONS FOR DAIRY ANIMAL TREATMENT - A method for mixing dairy animal teat dip from water and additives. The method includes a mixing manifold into which the water and additives are fed and mixed in a controlled manner. Mixed teat dip is automatically quality tested and monitored to provide data for controlling quantities of water and additives being fed to the manifold. | 12-24-2015 |
Solomon Chang, Taichung City TW
Patent application number | Description | Published |
---|---|---|
20090045776 | Power System - A power system comprises: a power unit; a portable electrical tool having a power line, which is electrically connected to the power unit; a power-store device being electrically connected to the power unit; wherein the power unit provides power to the portable electrical tool and the power-store device, the power-store device stores the power simultaneously, so that the power-store device provides the power to the portable electrical tool while in the condition of the power line being not connected to the power unit, such as outdoor works. | 02-19-2009 |
Solomon Coriiu, Bucharest RO
Patent application number | Description | Published |
---|---|---|
20150109899 | PIM FAST FAILOVER USING PIM GRAFT MESSAGE - A system for PIM fast failover recovery includes a network of a plurality of switching devices. The plurality of switching devices includes a source switching device near a source communicatively connected to a receiver switching device near a receiver by a first interface and at least a third switching device that is communicatively connected to the receiver switching device by a second interface and further is communicatively connected to the source switching device by a third interface. The receiver switching device may discover that the first interface has failed and responds by sending the third switching device a PIM graft message prior to deleting an associated first interface route entry. | 04-23-2015 |
20160094442 | PROTOCOL INDEPENDENT MULTICAST (PIM) REGISTER MESSAGE TRANSMISSION - Embodiments of the invention relate to register message transmission control in a system. One embodiment includes forwarding a communication packet to a first switch. A multicast source route entry is created by the first switch based on the communication packet. The communication packet is forwarded from the first switch to a second switch. A duplicate of the multicast source route entry is created by the second switch based on the forwarded communication packet. A register message is sent to a router by one of the first switch and the second switch based on a first vLAG role. Sending of a duplicate of the register message by one of the first switch and the second switch is prevented based on a second vLAG role. | 03-31-2016 |
20160094443 | PROTOCOL INDEPENDENT MULTICAST (PIM) MULTICAST ROUTE ENTRY SYNCHRONIZATION - Embodiments of the invention relate to synchronizing multicast route entries in a system. One embodiment includes forwarding a communication packet to a first switch and determining a multicast source route entry by the first switch based on the communication packet. The communication packet is forwarded from the first switch to a second switch. The multicast source route entry is determined by the second switch based on the forwarded communication packet. | 03-31-2016 |
Solomon Dadebo, East Amherst, NY US
Patent application number | Description | Published |
---|---|---|
20150101672 | HYDROGEN SUPPLY METHOD AND SYSTEM - A method and system for supplying additional hydrogen from a reservoir of stored hydrogen in a salt cavern to a hydrogen pipeline to assist in meeting customer demand for hydrogen is provided. Contaminants introduced while the stored hydrogen stream is in the salt cavern may cause the crude hydrogen stream to not have the required product purity specification. The stored hydrogen is removed from the salt cavern as a crude hydrogen stream and thereafter diluted with higher purity hydrogen formed from the pipeline to form a hydrogen product stream at or below the product purity specification. The hydrogen product can be formed without removal of any of the contaminants in the crude stream, thereby creating a more cost effective and simplified supply process compared to conventional processes employing a salt cavern for hydrogen supply. | 04-16-2015 |
Solomon Dadebo, Spring, TX US
Patent application number | Description | Published |
---|---|---|
20130213479 | HYDROGEN SUPPLY METHOD AND SYSTEM - A method and system for supplying additional hydrogen from a reservoir of stored hydrogen in a salt cavern to a hydrogen pipeline to assist in meeting customer demand for hydrogen is provided. Contaminants introduced while the stored hydrogen stream is in the salt cavern may cause the crude hydrogen stream to not have the required product purity specification. The stored hydrogen is removed from the salt cavern as a crude hydrogen stream and thereafter diluted with higher purity hydrogen formed from the pipeline to form a hydrogen product stream at or below the product purity specification. The hydrogen product can be formed without removal of any of the contaminants in the crude stream, thereby creating a more cost effective and simplified supply process compared to conventional processes employing a salt cavern for hydrogen supply. | 08-22-2013 |
Solomon Dadebo, Williamsville, NY US
Patent application number | Description | Published |
---|---|---|
20080243310 | Production control utilizing real time optimization - Method of controlling production of a plant incorporating one or more chemical processes in which products are produced through consumption of raw materials. In accordance with the method, current production rates of the products are computed by semi-empirical process models that are corrected through error corrections of actual production rates to produce corrected models. The production is then optimized using the corrected models to maximize the variable margin gained upon the sale of the products. The optimization yields targets that either directly or at least influence consumption of the raw materials. The raw materials are then introduced into the process or processes in accordance with the targets. | 10-02-2008 |
Solomon Dasary, Dallas, TX US
Patent application number | Description | Published |
---|---|---|
20100019035 | ARTICLE IDENTIFICATION SYSTEM - The present disclosure includes methods and systems for identifying articles. One method embodiment includes positioning a number of movable Faraday screens in particular locations relative to a number of different stages in a laundering process, and moving a mobile electronic identification device (EID) reader past the locations. | 01-28-2010 |
Solomon Emeth US
Patent application number | Description | Published |
---|---|---|
20120204307 | INTERACTIVE POINT OF PURCHASE SYSTEM - The system includes a garment having a series of electronic components affixed to a new or existing panel of said garment, which garment includes a flexible video display screen mounted on a portion of the garment outer surface and may contain a series of video cameras, communication systems, audio and video input and output devices, computer chips and transmission devices. A power generation system affixed to the garment or garment panel supplies the energy for its display. | 08-16-2012 |
Solomon Fallas US
Patent application number | Description | Published |
---|---|---|
20130213971 | DUAL USE BEVERAGE CUP - A stackable beverage cups and, in particular to a dual use stackable beverage cup that can be used both as a standard size cup and as a smaller shot size cup. | 08-22-2013 |
Solomon Fallas, Brooklyn, NY US
Patent application number | Description | Published |
---|---|---|
20120223082 | Dual Use Beverage Cup - A stackable beverage cups and, in particular to a dual use stackable beverage cup that can be used both as a standard size cup and as a smaller shot size cup. | 09-06-2012 |
20130213971 | DUAL USE BEVERAGE CUP - A stackable beverage cups and, in particular to a dual use stackable beverage cup that can be used both as a standard size cup and as a smaller shot size cup. | 08-22-2013 |
Solomon Ho, Anaheim, CA US
Patent application number | Description | Published |
---|---|---|
20100026912 | Multifunction display system - A multifunction display system is provided comprising a flat panel display screen; an electronic controller receiving video signal from an input and generating an output signal for displaying on the display screen; a power supply providing power to display screen and the electronic controller; a housing securing the display screen, the electronic controller and the power supply, wherein the housing includes a front shell and a rear shell that join together at a meeting line along a periphery of the display screen. The rear shell of the housing is a designed panel to receive multiple devices of specialized media playing capabilities in standardized boxes including but not limited to a regular or HD television tuner, a DVD and optical disc player, a digital video recorder, a hard drive player or an IPTV Divx player, mini PC and Internet and/or receiver router. | 02-04-2010 |
Solomon Iyasere, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20150050735 | WELL PLATES - Well plates for use in various laboratory experiments may include a plurality of wells each having an interior wall that includes a ledge positioned at a fixed depth within the well. | 02-19-2015 |
Solomon Kolagani, Ellicott City, MD US
Patent application number | Description | Published |
---|---|---|
20090078202 | SUBSTRATE HEATER FOR MATERIAL DEPOSITION - A radiative heater for substrates in a physical vapor deposition process for fabricating films of materials in a wide dynamic range of process temperatures and gas pressures includes a heat radiating member made from a high-temperature and oxidation resistant material tolerant to vacuum conditions which separates a heater volume containing heating filaments from a process volume which contains a deposition substrate heated by radiation of the walls of the heat radiating member. The heating elements extend through the body of the heat radiating member as well as in proximity to its surface to provide delivery of the heat to the substrate. The heat radiating member is shaped to form a cavity containing the substrate. The walls of the cavity envelope the substrate and radiate heat towards the substrate. Alternatively, the substrate is adhered to the flat surface of the heat radiating member. | 03-26-2009 |
Solomon Langermann, Baltimore, MD US
Patent application number | Description | Published |
---|---|---|
20090162933 | EPHA2 AND HYPERPROLIFERATIVE CELL DISORDERS - The present invention relates to methods and compositions designed for the treatment, management, or prevention of a non-neoplastic hyperproliferative cell or excessive cell accumulation disorders, particularly those involving hyperproliferation of epithelial or endothelial cells. In one embodiment, the methods of the invention comprise the administration of an effective amount of one or more EphA2 agonistic agents that bind to EphA2 and increase EphA2 cytoplasmic tail phosphorylation and/or increase EphA2 autophosphorylation, in cells which EphA2 has been agonized. In another embodiment, the methods of the invention comprise the administration of an effective amount of one or more EphA2 agonistic agents that bind to EphA2 and reduce EphA2 activity (other than autophosphorylation). In another embodiment, the methods of the invention comprise administration of an effective amount of one or more EphA2 agonistic agents that bind to EphA2 and decrease a pathology-causing cell phenotype (e.g., a pathology-causing epithelial cell phenotype or a pathology-causing endothelial cell phenotype). In another embodiment, the methods of the invention comprise the administration of an effective amount of one or more EphA2 agonistic agents that are EphA2 antibodies that bind to EphA2 with a very low K | 06-25-2009 |
20100055102 | COMPOSITIONS OF PD-1 ANTAGONISTS AND METHODS OF USE - Methods of treating cancer and infectious diseases utilizing a treatment regimen comprising administering a compound that reduces inhibitory signal transduction in T cells, in combination with a potentiating agent, such as cyclophosphamide, to produce potent T cell mediated responses, are described. Compositions comprising the PD-1 antagonists and potentiating agents useful in the methods of the invention are also disclosed. | 03-04-2010 |
20100278838 | EPHA2 MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF - The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. In one embodiment, the methods of the invention comprise the administration of an effective amount of an antibody that binds to EphA2 and agonizes EphA2, thereby increasing EphA2 phosphorylation and decreasing EphA2 levels. In other embodiments, the methods of the invention comprise the administration of an effective amount of an antibody that binds to EphA2 and inhibits cancer cell colony formation in soft agar, inhibits tubular network formation in three-dimensional basement membrane or extracellular matrix preparation, preferentially binds to an EphA2 epitope that is exposed on cancer cells but not non-cancer cells, and/or has a low K | 11-04-2010 |
20110159023 | PD-1 ANTAGONISTS AND METHODS FOR TREATING INFECTIOUS DISEASE - Methods and compositions for treating an infection or disease that results from (1) failure to elicit rapid T cell mediated responses, (2) induction of T cell exhaustion, T cell anergy or both, or (3) failure to activate monocytes, macrophages, dendritic cells and/or other APCs, for example, as required to kill intracellular pathogens. The method and compositions solve the problem of undesired T cell inhibition by binding to and blocking PD-1 to prevent or reduce inhibitory signal transduction, or by binding to ligands of PD-1 such as PD-L1, thereby preventing (in whole or in part) the ligand from binding to PD-1 to deliver an inhibitory signal. The immune response can be modulated by providing antagonists which bind with different affinity (i.e., more or less as required), by varying the dosage of agent which is administered, by intermittent dosing over a regime, and combinations thereof, that provides for dissociation of agent from the molecule to which it is bound prior to being administered again (similar to what occurs with antigen elicitation using priming and boosting). In some cases it may be particularly desirable to stimulate the immune system, then remove the stimulation. | 06-30-2011 |
20110195068 | PD-1 ANTAGONISTS AND METHODS OF USE THEREOF - Compositions and methods for enhancing and/or prolonging the activation of T cells (i.e., increasing antigen-specific proliferation of T cells, enhancing cytokine production by T cells, stimulating differentiation ad effector functions of T cells and/or promoting T cell survival) or overcoming T cell exhaustion and/or anergy are provided. Suitable compositions include PD-1 receptor antagonists that bind to and block the endogenous PD-1 receptor without triggering inhibitory signals from PD-1, or bind to and block PD-1 receptor ligands and preventing them from interacting with PD-1 receptors. Methods for using the PD-1 receptor antagonists to enhance immune responses in subjects in need thereof are provided. | 08-11-2011 |
20110223188 | TARGETED COSTIMULATORY POLYPEPTIDES AND METHODS OF USE TO TREAT CANCER - Compositions are provided that are targeted to tumors or tumor-associated neovasculature and enhance the function of tumor-infiltrating T cells. The compositions include fusion proteins that contain a T cell binding domain and a tumor/tumor-associated neovasculature targeting domain. The fusion proteins optionally contain a peptide/polypeptide linker domain and a domain that mediates dimerization or multimerization. The T cell binding domain can be a costimulatory molecule. Methods for using the fusion proteins to enhance an immune response are provided. Therapeutic uses for the disclosed compositions include the induction of tumor immunity. | 09-15-2011 |
20120114648 | COMPOSITIONS OF PD-1 ANTAGONISTS AND METHODS OF USE - Methods of treating cancer and infectious diseases utilizing a treatment regimen comprising administering a compound that reduces inhibitory signal transduction in T cells, in combination with a potentiating agent, such as cyclophosphamide, to produce potent T cell mediated responses, are described. Compositions comprising the PD-1 antagonists and potentiating agents useful in the methods of the invention are also disclosed. | 05-10-2012 |
20120114649 | COMPOSITIONS OF PD-1 ANTAGONISTS AND METHODS OF USE - Methods of treating cancer and infectious diseases utilizing a treatment regimen comprising administering a compound that reduces inhibitory signal transduction in T cells, in combination with a potentiating agent, such as cyclophosphamide, to produce potent T cell mediated responses, are described. Compositions comprising the PD-1 antagonists and potentiating agents useful in the methods of the invention are also disclosed. | 05-10-2012 |
20120177645 | METHODS AND COMPOSITIONS FOR THE INHIBITION OF TRANSPLANT REJECTION - Methods for modulating immune responses in a subject are provided. A preferred embodiment provides methods and compositions for reducing or inhibiting transplant rejection in a subject, preferably a human subject. Transplant rejection can be inhibited or reduced in a subject by administering an effective amount of B7-H4 polypeptide, fragments or fusions thereof to inhibit or reduce the biological activity of an immune cell or to reduce the amounts of proinflammatory molecules at a site of transplant. Th1, Th17 and Th22 cells are exemplary T cells that can be targeted for inhibition by B7-H4 polypeptides, fusion proteins or fragments thereof to inhibit or reduce inflammation. | 07-12-2012 |
20120276095 | B7-H4 FUSION PROTEINS AND METHODS OF USE THEREOF - Fusion proteins containing B7-H4 polypeptides are disclosed. The B7-H4 fusion proteins can include full-length B7-H4 polypeptides, or can contain a fragment of a full-length B7-H4 polypeptide, including some or all of the extracellular domain of the B7-H4 polypeptide. Methods for using the fusion proteins to downregulate T cell activation and for the treatment of inflammatory and autoimmune diseases and disorders are also disclosed. The B7-H4 fusion proteins are useful for treating inflammation by inhibiting or reducing differentiation, proliferation, activity, and/or cytokine production and/or secretion by ThI, ThI 7, Th22, and/or other cells that secrete, or cause other cells to secrete, inflammatory molecules, including, but not limited to, IL-1β, TNF-α, TGF-beta, IFN-γ, IL-17, IL-6, IL-23, IL-22, IL-21, and MMPs; or enhancing IL-IO secretion by Tregs, increasing the differentiation of Tregs, increasing the number of Tregs, or combinations thereof. | 11-01-2012 |
20130017199 | SIMULTANEOUS INHIBITION OF PD-L1/PD-L2 - Methods and compositions for treating an infection or disease that results from (1) failure to elicit rapid T cell mediated responses, (2) induction of T cell exhaustion, T cell anergy or both, or (3) failure to activate monocytes, macrophages, dendritic cells and/or other APCs, for example, as required to kill intracellular pathogens. The method and compositions solve the problem of undesired T cell inhibition by simultaneously inhibiting the PD-1 ligands, PD-L1 and PD-L2. The immune response can be modulated by providing antagonists which bind with different affinity, by varying the dosage of agent which is administered, by intermittent dosing over a regime, and combinations thereof, that provides for dissociation of agent from the molecule to which it is bound prior to being administered again. In some cases it may be particularly desirable to stimulate the immune system, then remove the stimulation. | 01-17-2013 |
20130230514 | COMPOSITIONS OF PD-1 ANTAGONISTS AND METHODS OF USE - Methods of treating cancer and infectious diseases utilizing a treatment regimen comprising administering a compound that reduces inhibitory signal transduction in T cells, in combination with a potentiating agent, such as cyclophosphamide, to produce potent T cell mediated responses, are described. Compositions comprising the PD-1 antagonists and potentiating agents useful in the methods of the invention are also disclosed. | 09-05-2013 |
20140044738 | Antibodies And Other Molecules That Bind B7-H1 And PD-1 - The present invention relates to antibodies and their antigen-binding fragments and to other molecules that are capable of immunospecifically binding to B7-H1 or PD-1. In some embodiments such molecules are additionally capable of modulating the ability of B7-H1 or B7-DC to bind to PD-1 or are capable of affecting the signaling activity of the B7-H1 or PD-1. The invention additionally concerns the uses of such molecules in the diagnosis and treatment of cancer and other diseases. | 02-13-2014 |
20140356364 | Anti-B7-H4 Antibodies and Their Uses - The present invention relates to antibodies (including anti-B7-H4 antibodies) and their antigen-binding fragments and to other molecules (including fusion proteins that bind to the cognate antigen/receptor, etc.) that are capable of immunospecifically binding to B7-H4 and the uses of such molecules in the diagnosis and the treatment of cancer and other diseases. The invention particularly concerns the use of such molecules to retard or prevent tumor growth, inhibit tumor-mediated suppression, eliminate tumors and/or deplete or block the activity of tumor associated macrophages (“TAMs”) so as to alter their activity and/or decrease TAM—mediated immune suppression. | 12-04-2014 |
20150315275 | ANTI-HUMAN B7-H4 ANTIBODIES AND THEIR USES - Anti-human B7-H4 antibody “6H3”, antigen-binding fragments, derivatives, and humanized variants thereof that are capable of immmospecifically binding to B7-H4, and the uses of such molecules in the diagnosis and the treatment of cancer and other diseases are disclosed. In preferred embodiments, the molecules are used to retard or prevent tumor growth, inhibit tumor-mediated suppression, eliminate tumors and/or deplete or block the activity of tumor-associated macrophages (“TAMs”) so as to alter their activity and/or decrease TAM-mediated immune suppression. | 11-05-2015 |
20160024210 | ANTI-H7CR ANTIBODIES - Antibodies and humanized variants thereof and their antigen-binding fragments and to other molecules that are capable of immunospecifically binding to the B7-H7 counter-receptor, H7CR, and their uses in enhancing immune responses and the treatment and diagnosis of cancer and other diseases are provided. | 01-28-2016 |
20160039905 | B7-H4 FUSION PROTEINS AND METHODS OF USE THEREOF - Fusion proteins containing B7-II4 polypeptides are disclosed. The B7-H4 fusion proteins can include full-length B7-H4 polypeptides, or can contain a fragment of a full-length B7-H4 polypeptide, including some or all of the extracellular domain of the B7-H4 polypeptide. Methods for using the fusion proteins to downregulate T cell activation and for the treatment of inflammatory and autoimmune diseases and disorders are also disclosed. The B7-H4 fusion proteins are useful for treating inflammation by inhibiting or reducing differentiation, proliferation, activity, and/or cytokine production and/or secretion by Th1, Th1 7, Th22, and/or other cells that secrete, or cause other cells to secrete, inflammatory molecules, including, but not limited to, IL-1β, TNF-α, TGF-beta, IFN-γ, IL-17, IL-6, IL-23, IL-22, IL-21, and MMPs; or enhancing IL-IO secretion by Tregs, increasing the differentiation of Tregs, increasing the number of Tregs, or combinations thereof. | 02-11-2016 |
20160039906 | METHODS AND COMPOSITIONS FOR THE INHIBITION OF TRANSPLANT REJECTION - Methods for modulating immune responses in a subject are provided. A preferred embodiment provides methods and compositions for reducing or inhibiting transplant rejection in a subject, preferably a human subject. Transplant rejection can be inhibited or reduced in a subject by administering an effective amount of B7-H4 polypeptide, fragments or fusions thereof to inhibit or reduce the biological activity of an immune cell or to reduce the amounts of proinflammatory molecules at a site of transplant. Th1, Th17 and Th22 cells are exemplary T cells that can be targeted for inhibition by B7-H4 polypeptides, fusion proteins or fragments thereof to inhibit or reduce inflammation. | 02-11-2016 |
20160096891 | ANTI-B7-H5 ANTIBODIES AND THEIR USES - The present invention relates to antibodies and their antigen-binding fragments and to other molecules that are capable of immunospecifically binding to the B7-H5 ligand of the B7-H5:CD28H pathway, and to the uses of such molecules in the treatment and diagnosis of autoimmune disease, transplant rejection and other inflammatory diseases. | 04-07-2016 |
Solomon Lee, Newhall, CA US
Patent application number | Description | Published |
---|---|---|
20130105379 | Magnetic Fluid Filter | 05-02-2013 |
Solomon Levy, Chula Vista, CA US
Patent application number | Description | Published |
---|---|---|
20160037881 | EARRING WITH LATCHING MECHANISM - A latching mechanism for an earring having two opposed ends. A post with a notch at one end is affixed to one of the opposed ends. The post is used to hold the earring in place when inserted into a pierced earlobe. A post engagement element is affixed to the second opposed end and rotates around a pin. The post engagement element includes a catch for engaging the notch. A spring receiving chamber is affixed to the earring adjacent to the second opposed end. A spring is disposed into the spring receiving chamber, and operates to apply a biasing force on the post engagement element for enabling the notch and the catch to engage with each other. When a force is applied to the post engagement element, the spring is compressed and the post engagement element rotates around the pin and disengages the notch from the catch. | 02-11-2016 |
Solomon Li, Burlingame, CA US
Patent application number | Description | Published |
---|---|---|
20160106910 | INSULIN PUMP DATA ACQUISITION DEVICE - An insulin pump data acquisition device including: an insulin pump casing having an interior volume; an environmental sensor operable to generate environmental data in response to environmental conditions; memory operably connected to the environmental sensor, the memory being operable to store the environmental data; a controller operably connected to the environmental sensor and the memory, the controller being operable to control reading of the environmental data from the environmental sensor and writing of the environmental data to the memory; and a battery operably connected to power the environmental sensor, the memory, and the controller; wherein the environmental sensor, the memory, the controller, and the battery are disposed within the interior volume. | 04-21-2016 |
Solomon Lo, Brooklyn Center, MN US
Patent application number | Description | Published |
---|---|---|
20140324662 | Systems and Methods for Trading Electrical Power - Systems and methods are provided, which facilitate the integration of energy trading, transmission management and scheduling. The systems and methods facilitate the posting of bids and offers to buy and sell energy or capacity, allow users to view the bids and offers of others, negotiate the details of bids and offers, and permit deal formation for the purchase and sale of bids and offers. The disclosure also facilitates issuing proposals and counteroffers to enter into deals for power transmission. The disclosure also enables the scheduling of transmission including facilitating communication with various other systems. The disclosed systems and methods further enable the creation, modification and storing of transmission paths for recall and then evaluation in the scheduling of transmission path. The systems and methods are linked to and receive input from various sources of data and may facilitate two way communication with other systems in order to enable certain functionality. | 10-30-2014 |
Solomon Ofori-Acquah, Decatur, GA US
Patent application number | Description | Published |
---|---|---|
20130123185 | METHODS OF TREATING AND DIAGNOSING ACUTE CHEST SYNDROME - In certain embodiments, the disclosure relates to methods of treating or preventing organ inflammation or failure such as pulmonary inflammation comprising administering a heme scavenger such as hemopexin to a subject in need thereof. The subject may be diagnosed with higher than normal levels of protein-free plasma heme or a hemolytic disorder such as sickle cell disease, autoimmune hemolytic anemia, or paroxysmal nocturnal hemoglobinuria or acute lung injury or acute chest syndrome. Typically, the hemopexin is recombinant human hemopexin. | 05-16-2013 |
Solomon Ofori-Ansah, Plano, TX US
Patent application number | Description | Published |
---|---|---|
20110028249 | Iso-Soccer - The invention disclosed is a sport and a game and comprises a sport court that accommodates a number of players in the play of the game, a set of rules and regulations by which the game is played, and a method of playing the game by an inflated leather ball. The sport court is a square with four equal-sized goalposts at each side enclosed by a perimeter fence. The floor of the sport court and the inward side of the perimeter fence are demarcated with lines such that respectively, they serve as horizontal and vertical playing surfaces for the ball. | 02-03-2011 |
Solomon Ssenyange, Fremont, CA US
Patent application number | Description | Published |
---|---|---|
20130219995 | OBTAINING SELECTIVITY IN GAS SENSORS VIA A SENSOR ARRAY SYSTEM COMPOSED OF P AND N TYPE MATERIAL - Systems and methods for discriminating among volatile compounds is provided using a semiconductor junction structure or sensor device. Sensor devices of the present disclosure employ a combination of hole carriers (p-type) and electron carriers (n-type) metal oxides deposited, for example, on a gold microspring array designed so that it has several leads that are at different distances from each other. | 08-29-2013 |
20150250408 | Respiratory Monitor - A respiratory monitor is disclosed that includes features for conducting multiple pulmonary function tests in a single device and for detecting the presence of nitric oxide in exhaled breath. Also described is a mouthpiece that allows for separate inhalation and exhalation pathways and for filtering inhaled and exhaled breath for predetermined species prior to exhalation into the respiratory monitor. The monitor further allows for wired, wireless and network connectivity and for cloud-based systems for communicating and correlating pulmonary data as well as relevant environmental data and displaying the data for use by patients and health care professionals. | 09-10-2015 |
Solomon Ssenyange US
Patent application number | Description | Published |
---|---|---|
20130219995 | OBTAINING SELECTIVITY IN GAS SENSORS VIA A SENSOR ARRAY SYSTEM COMPOSED OF P AND N TYPE MATERIAL - Systems and methods for discriminating among volatile compounds is provided using a semiconductor junction structure or sensor device. Sensor devices of the present disclosure employ a combination of hole carriers (p-type) and electron carriers (n-type) metal oxides deposited, for example, on a gold microspring array designed so that it has several leads that are at different distances from each other. | 08-29-2013 |
Solomon Ugashe, Fremont, CA US
Patent application number | Description | Published |
---|---|---|
20080293717 | ARYL SULFONAMIDES - Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists. | 11-27-2008 |
20090118307 | Aryl Sulfonamides - Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists. | 05-07-2009 |
20090270616 | ARYL SULFONAMIDES - Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists. | 10-29-2009 |
20110021523 | ARYL SULFONAMIDES - Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists. | 01-27-2011 |
Solomon Wu, Milpitas, CA US
Patent application number | Description | Published |
---|---|---|
20100217861 | METHOD AND SYSTEM FOR MULTICAST STATISTIC COLLECTION | 08-26-2010 |
Solomon Zittrer, Houston, TX US
Patent application number | Description | Published |
---|---|---|
20120305095 | CPVC PIPES, FITTINGS AND TUBULAR CONDUITS IN MARINE VESSELS - A marine vessel ( | 12-06-2012 |